California high court rules for Gilead, says drugmakers have no duty to innovate

• The case involved Gilead's decision in 2004 to halt development of TAF, an HIV drug with fewer kidney and bone side effects than its existing TDF drug, which patients claimed was timed to maximize the $27 billion profit window before TDF's 2017 patent expiration.
• HIV drugs accounted for 70% of Gilead's $29.4 billion revenue last year, and major pharmaceutical companies including Pfizer, Merck, and Johnson & Johnson supported Gilead's position that a duty to innovate would make drug development too costly.
• The sole dissenting justice called Gilead's conduct 'morally blameworthy' and urged California's legislature to consider eliminating drugmakers' immunity from negligence claims, noting the industry already enjoys patent protection and strict liability exemptions.

Summary: California Supreme Court Rules Against "Duty to Innovate" for Drugmakers in Gilead Case

Key Decision:

The California Supreme Court ruled 6-1 in favor of Gilead Sciences, ordering dismissal of negligence claims brought by approximately 24,000 HIV patients. The court rejected the concept of a "duty to innovate," determining that pharmaceutical companies are not legally obligated to develop safer alternative drugs when existing medications are deemed safe.

Case Background:

Patients sued Gilead over its decision to halt development of tenofovir alafenamide fumarate (TAF) in 2004, a drug with fewer side effects than the company's existing HIV treatment containing tenofovir disoproxil fumarate (TDF). TDF, approved in 2001, carried risks including kidney dysfunction and bone problems. Plaintiffs alleged Gilead deliberately delayed TAF's commercialization until 2017 to maximize profits as TDF's patent exclusivity expired, resulting in $27 billion in additional revenue.

Financial Context:

HIV drugs generated 70% of Gilead's $29.4 billion revenue in the previous year, underscoring the financial significance of this product line.

Legal Rationale:

Justice Joshua Groban stated that imposing a duty to innovate would force juries to second-guess complex scientific decisions in hindsight and create substantial burdens that could harm pharmaceutical innovation, public health, and patient safety. The ruling reversed a February 2024 lower court decision.

Industry Impact:

The decision has broad implications for pharmaceutical liability law. Major drugmakers including Bayer, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, and Pfizer supported Gilead's position. Industry critics had warned that such liability would make drug development prohibitively costly.

Dissent:

Justice Kelli Evans dissented, calling Gilead's conduct "morally blameworthy" and urging legislative action.